

Study Number: 108020007
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,2-Dichlorobenzene
CAS Number: 95-50-1

Date Report Requested: 09/26/2025
Time Report Requested: 15:59:03
Lab: Battelle

Study Number: 108020007
Study Sex: Female
PWG Approval Date: See web page for date of PWG Approval
Version: v1.7.2-6-ge85fa364
Stat Version: 2023.02.27S

Study Number: 108020007
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,2-Dichlorobenzene
CAS Number: 95-50-1

Date Report Requested: 09/26/2025
Time Report Requested: 15:59:03
Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups (ppm)				
		0	1	10	30	100
Urea Nitrogen (mg/dL)	SD 5	17.0 ± 0.9 (7)	15.0 ± 0.0 (2)	15.0 ± 0.0 (2)	19.7 ± 2.0 (3)	16.3 ± 0.5 (4)
Percent of Control			88.2	88.2	115.7	95.6
Creatinine (mg/dL)	SD 5	0.20 ± 0.00 (7)	0.20 ± 0.04 (4)	0.20 ± 0.00 (2)	0.20 ± 0.00 (3)	0.20 ± 0.00 (4)
Percent of Control			100.0	100.0	100.0	100.0
Glucose (mg/dL)	SD 5	155.8 ± 4.8 (6)	159.0 ± 0.0 (2)	162.5 ± 5.5 (2)	148.0 ± 1.0 (2)	167.3 ± 2.0 (3)
Percent of Control			102.0	104.3	95.0	107.4
Total Protein (g/dL)	SD 5	5.75 ± 0.08 (6)	5.90 ± 0.20 (2)	5.90 ± 0.10 (2)	5.85 ± 0.05 (2)	5.80 ± 0.06 (3)
Percent of Control			102.6	102.6	101.7	100.9
Globulin (g/dL)	SD 5	1.56 ± 0.21 (5)	1.55 ± 0.15 (2)	1.55 ± 0.05 (2)	1.30 (1)	1.40 (1)
Percent of Control			99.4	99.4	83.3	89.7
A/G Ratio	SD 5	2.88 ± 0.35 (5)	2.83 ± 0.24 (2)	2.81 ± 0.19 (2)	3.46 (1)	3.14 (1)
Percent of Control			98.3	97.7	120.2	109.2
Albumin (g/dL)	SD 5	4.20 ± 0.16 (5)	4.35 ± 0.05 (2)	4.35 ± 0.15 (2)	4.50 (1)	4.40 (1)
Percent of Control			103.6	103.6	107.1	104.8
Cholesterol (mg/dL)	SD 5	115.8 ± 4.9 (5) **	126.5 ± 15.5 (2)	129.0 ± 13.0 (2)	133.0 (1)	141.0 (1)
Percent of Control			109.2	111.4	114.9	121.8
Triglyceride (mg/dL)	SD 5	113.8 ± 7.7 (5)	126.5 ± 39.5 (2)	125.5 ± 28.5 (2)	118.0 (1)	101.0 (1)
Percent of Control			111.2	110.3	103.7	88.8
Alanine Aminotransferase (IU/L)	SD 5	58.9 ± 11.8 (8) **	102.8 ± 45.6 (4)	40.0 ± 2.0 (2)	78.3 ± 12.2 (3)	84.2 ± 17.3 (5)
Percent of Control			174.5	67.9	133.1	143.0
Alkaline Phosphatase (IU/L)	SD 5	191.5 ± 8.1 (8) **	234.8 ± 9.7 (4)	159.5 ± 26.5 (2)	175.7 ± 11.9 (3)	129.2 ± 5.3 (5) **
Percent of Control			122.6	83.3	91.7	67.5

Study Number: 108020007
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,2-Dichlorobenzene
CAS Number: 95-50-1

Date Report Requested: 09/26/2025
Time Report Requested: 15:59:03
Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups (ppm)				
		0	1	10	30	100
Aspartate Aminotransferase (U/L) Percent of Control	SD 5	123.29 ± 10.06 (7) *	101.00 ± 10.00 (2) 81.9	92.50 ± 16.50 (2) 75.0	172.00 ± 31.95 (3) 139.5	110.25 ± 7.90 (4) 89.4
Creatine Kinase (IU/L) Percent of Control	SD 5	824.7 ± 128.0 (6)	755.0 ± 12.0 (2) 91.6	648.0 ± 288.0 (2) 78.6	1050.5 ± 71.5 (2) 127.4	856.0 ± 152.6 (3) 103.8
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 5	25.6 ± 1.1 (7) **	28.0 ± 0.1 (2) 109.4	28.9 ± 4.4 (2) 112.8	22.0 ± 5.5 (3) 86.1	40.9 ± 6.7 (4) ** 159.9
Bile salt/acids (µmol/L) Percent of Control	SD 5	4.2 ± 0.7 (5) *	3.0 ± 1.0 (2) 71.4	4.0 ± 0.0 (2) 95.2	4.0 (1) 95.2	4.0 (1) 95.2

Study Number: 108020007
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,2-Dichlorobenzene
CAS Number: 95-50-1

Date Report Requested: 09/26/2025
Time Report Requested: 15:59:03
Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups
		250
Urea Nitrogen (mg/dL)	SD 5	15.1 ± 0.7 (7)
Percent of Control		89.1
Creatinine (mg/dL)	SD 5	0.17 ± 0.02 (7)
Percent of Control		85.7
Glucose (mg/dL)	SD 5	131.0 ± 7.3 (4)
Percent of Control		84.1
Total Protein (g/dL)	SD 5	5.80 ± 0.23 (4)
Percent of Control		100.9
Globulin (g/dL)	SD 5	1.53 ± 0.10 (4)
Percent of Control		97.8
A/G Ratio	SD 5	2.82 ± 0.11 (4)
Percent of Control		98.1
Albumin (g/dL)	SD 5	4.28 ± 0.13 (4)
Percent of Control		101.8
Cholesterol (mg/dL)	SD 5	194.3 ± 10.3 (4) **
Percent of Control		167.7
Triglyceride (mg/dL)	SD 5	180.5 ± 30.7 (4)
Percent of Control		158.6
Alanine Aminotransferase (IU/L)	SD 5	248.6 ± 34.2 (7) **
Percent of Control		422.2
Alkaline Phosphatase (IU/L)	SD 5	109.4 ± 3.1 (7) **
Percent of Control		57.1

Study Number: 108020007
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,2-Dichlorobenzene
CAS Number: 95-50-1

Date Report Requested: 09/26/2025
Time Report Requested: 15:59:03
Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups
		250
Aspartate Aminotransferase (U/L)	SD 5	261.57 ± 53.21 (7)
Percent of Control		212.2
Creatine Kinase (IU/L)	SD 5	420.3 ± 99.4 (4)
Percent of Control		51.0
Sorbitol Dehydrogenase (IU/L)	SD 5	108.6 ± 7.0 (7) **
Percent of Control		424.3
Bile salt/acids (µmol/L)	SD 5	13.0 ± 3.0 (4)
Percent of Control		309.5

Study Number: 108020007
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Mouse/B6D2F1/Crl

PA41: Clinical Chemistry Summary
Test Compound: 1,2-Dichlorobenzene
CAS Number: 95-50-1

Date Report Requested: 09/26/2025
Time Report Requested: 15:59:03
Lab: Battelle

LEGEND

Values given as mean \pm SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100.

SD = Study Day

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Data with sample size of 1 in the treatment group were included in trend test, but excluded from the multiple comparisons tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at $p \leq 0.05$

** Statistically significant at $p \leq 0.01$

Control and some treated animals' total and direct bilirubin values were below linearity, consistent with normal baseline concentrations. The number of samples that were above linearity was low, thus no statistical analysis was conducted for these endpoints.

Clinical chemistry data not reported was removed as an outlier, or was due to pre-analytical or analytical conditions or errors including but not limited to: below linearity, short sample, quantity not sufficient, or extreme hemolysis.

**** END OF REPORT ****